# OnCo record paper-magnolia-zanubrutinib-mzl-ccr-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-magnolia-zanubrutinib-mzl-ccr-2021" ;
  schema:name "MAGNOLIA: zanubrutinib in relapsed or refractory marginal zone lymphoma"@en ;
  schema:description "The BTK inhibitor zanubrutinib produced responses in about two thirds of patients with relapsed marginal zone lymphoma across all subtypes with few of the cardiac side effects seen with ibrutinib, leading to its approval."@en ;
  schema:url <https://onco.cc/key-papers/paper-magnolia-zanubrutinib-mzl-ccr-2021/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-21-1704>, <https://pubmed.ncbi.nlm.nih.gov/34526366/> ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.CCR-21-1704> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Opat S, Tedeschi A, Linton K, et al." ;
  onco:cancers <https://onco.cc/cancers/marginal-zone-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/zanubrutinib/> ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .